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Editorial 
New Drugs, New Directions? Research priorities for New Psychoactive Substances and Human 
Enhancement Drugs  
  
 Introduction 
 
This special issue of the International Journal of Drug Policy ĨŽĐƵƐĞƐŽŶ ‘ŶĞǁĚƌƵŐƐ ? ?ĚƌĂǁŝŶŐŽŶ
contributions to an Economic and Social Research Council (ESRC) seminar series 
(https://newdrugseminars.wordpress.com ?ǁĞĞŵďĂƌŬĞĚƵƉŽŶŝŶ ? ? ? ? ?DŽƐƚĐŽŵŵŽŶůǇ ? ‘ŶĞǁ
ĚƌƵŐƐ ?ĂƌĞĐŽŶĐĞƉƚƵĂůŝƐĞĚĂƐ ‘EĞǁWƐǇĐŚŽĂĐƚŝǀĞ^ƵďƐƚĂŶĐĞƐ ? ?EW^ ? W chemical compounds that have 
been newly and recently created, although some were synthesised many years ago with new 
evidence of sale and use. Others have been designed to mimic the effects of existing illegal drugs 
such as cannabis, MDMA, cocaine, LSD and heroin, and originally emerged outside the confines of 
ĐƵƌƌĞŶƚŶĂƚŝŽŶĂůĂŶĚŝŶƚĞƌŶĂƚŝŽŶĂůƐǇƐƚĞŵƐŽĨĚƌƵŐĐŽŶƚƌŽů ?ĂůƐŽǀĂƌŝŽƵƐůǇŬŶŽǁŶĂƐ ‘ĚĞƐŝŐŶĞƌĚƌƵŐƐ ? ?
 ‘ƐǇŶƚŚĞƚŝĐĚƌƵŐƐ ?ĂŶĚ ?Žƌ ‘ůĞŐĂůŚŝŐŚƐ ? ?WĞƌƌŽŶĞ ? ? ? ? ? ? ?EW^ŚĂǀĞďĞĞŶďƌŽĂĚůǇĐĂƚĞŐŽƌŝƐĞĚ ?hEK ?
2013) as: synthetic cannabinoid receptor agonists (e.g. JWH- ? ? ? ? ‘^ƉŝĐĞ ? ? ?ĂŵŝŶŽŝŶĚĂŵĞƐ ?Ğ ?Ő ?
MDAI), synthetic cathinones (e.g. Mephedrone), tryptamines (e.g. 5-Meo-DPT), ketamine and 
phencyclidine type substances (e.g. 4-MeO-PCP), plant based substances (e.g. khat), piperazines (e.g. 
Benzylpiperazine), phenethylamines (e.g. Bromo-DragonFLY), and other substances (e.g. DMAA).  
The design and manufacture of such substances is not a new phenomenon per se (Sumnall, 
EvansBrown & McVeigh, 2011), but the speed with which such substances have emerged over the 
last decade, the role that the Internet plays in facilitating their marketing and distribution, and their 
ŝŶĐƌĞĂƐŝŶŐůǇƚƌĂŶƐŶĂƚŝŽŶĂůŶĂƚƵƌĞ ?DĞĂƐŚĂŵ ? ? ? ? ? ?^ĞĚĚŽŶ ? ? ? ?  ?ŚĂǀĞůĞĚƚŽĂƐŝŐŶŝĨŝĐĂŶƚ “ŝŶĐƌĞĂƐĞ
ŝŶƚŚĞŝƌƌĂŶŐĞ ?ƉŽƚĞŶĐǇ ?ƉƌŽĨŝůĞĂŶĚĂǀĂŝůĂďŝůŝƚǇ ?(Winstock & Ramsey, 2010: 1685).    
 
 
ďƌŽĂĚĞƌŝŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨƚŚĞĨŝĞůĚŽĨ ‘ŶĞǁĚƌƵŐƐ ?ĂůƐŽŝŶĐůƵĚĞƐƐƵďƐƚĂŶĐĞƐŐĞŶĞƌĂůůǇĚĞƐĐƌŝďĞĚĂƐ
Human Enhancement Drugs (HED).   Evans-Brown, McVeigh, Perkins & Bellis (2012) describe how 
these are divided into six categories: muscle drugs (e.g. Anabolic-Androgenic Steroids), weight loss 
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drugs (e.g. Xenical), image enhancing drugs (e.g. Melanotan), sexual enhancers (e.g. Viagara), 
cognitive enhancers (e.g. Ritalin), and mood and behaviour enhancers (e.g. Diazepam).  Human 
Enhancement Drugs have not received the popular, media or research attention that have been 
afforded to new psychoactive substances, and subsequently, even less is known about them.  
Nevertheless, there are important similarities between NPS and HED that merit their joint study by 
those who are interested in the latest developments in the illicit drug field.  For example, there is a 
similar lack of information about rapidly emerging substances, there has been a similar tendency for 
countries such as Sweden, Denmark and Belgium to adopt zero-tolerance measures (Mulrooney  & 
van de Ven, 2015) on a precautionary basis, and they share similar online distribution methods.   
   
 
New Drugs: New Policies  
 
Over the last decade, two contrasting stories about the scope of the NPS problem have emerged.  A 
focus on the number of substances detected by monitoring systems such as the EMCDDA/Europol 
early warning system (EMCDDA & Europol, 2015) and the rate at which they are emerging, suggests 
that the problem is escalating at an exponential rate.  For example, the EMCDDA document (2016a) 
98 new substances reported to their early warning system in 2015, with more than 560 substances 
currently being monitored in the European Union (EU). The UN has thus described the new drugs 
phenomenon as the latest challenge faced by national and international systems of drug control 
(UNODC, 2013).  On the other hand, the limited available data suggests that general population use 
of these substances remains relatively low (European Commission, 2014; Measham & Newcombe, 
2016; Sumnall, Brown & McVeigh 2013).   
 
While some substances appeared to have successfully diffused into the street pharmacopeia, for 
example mephedrone in the UK (e.g. Carhart-Harris, King & Nutt, 2011) and Benzylpiperazine (BZP) 
in New Zealand (e.g. Sheridan and Butler, 2010), and while some populations have experienced 
higher levels of use, for example gay men and vulnerable populations (Atkinson, Begley & Sumnall, 
2016; Measham, Wood, Dargan & Moore, 2011), most oĨƚŚĞŵ “ŚĂƌĚůǇƌĞŐŝƐƚĞƌŽŶƚŚĞƌĂĚĂƌ ?
 ?^ŚĂƉŝƌŽ ? ? ? ? ? P ? ? ?ZĞƵƚĞƌ ? ? ? ? ? P ? ?ĚĞƐĐƌŝďĞƐƚŚĞƉƌŽďůĞŵĂƐ “ŵŽĚĞƐƚĂŶĚůŽĐĂůŝǌĞĚ ? ?ĂŶĚƐƵŐŐĞƐƚƐ
that there have not, thus far, been large numbers of fatalities and/or infections associated with this 
set of substances.  There have, however, been some recent notable localised examples:  multiple 
fatalities in Russia associated with use of what was identified as the synthetic cannabinoid 
MDMB(N)-Bz-F (RT News, 2014); a localised outbreak of HIV associated with NPS injection in Dublin, 
/ƌĞůĂŶĚ ?'ŝĞƐĞ ?/ŐŽĞ ?'ŝďďŽŶƐ ?,ƵƌůĞǇ ?^ƚŽŬĞƐ ?DĐEĂŵĂƌĂ ?ŶŶŝƐ ?K ?ŽŶŶĞůů ?<ĞĞŶĂŶ ?Ğ'ĂƐĐƵŶ ?
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Lyons, Ward, Danis, Glynn, Waters & Fitzerald, 2015).  Furthermore, Coulson & Caulkins (2011) failed 
to find significant violent markets associated with NPS. 
 
Nevertheless, NPS are being used as a catalyst for the rapid development of new policy responses 
(Chatwin, 2014; EMCDDA, 2016b; Measham & Newcombe, 2016; Stevens and Measham, 2014).  NPS 
tend to emerge rapidly, and sometimes in tandem with each other, making it difficult for existing 
reactive systems of drug control to keep pace with them.  Under systems that modify or adapt 
existing laws and processes, once legislation is passed to prohibit a named substance or group of 
substances (generic control), compounds can be easily moderated to create others not covered by 
ƚŚĞůĞŐŝƐůĂƚŝŽŶ ?ǀĂŶŵƐƚĞƌĚĂŵ ?EƵƚƚ ?ǀĂŶĚĞŶƌŝŶŬ ? ? ? ? ? Ă ‘ĐĂƚĂŶĚŵŽƵƐĞ ?ƌĞƐƉŽŶƐĞďĞƚǁĞĞŶ
policy makers and manufacturers noted since the earliest NPS appeared (Measham et al. 2011).  
  
Increasingly, demands have thus been placed on national and international drug control systems to 
adapt their existing drug laws to make them more effective in responding to NPS (Measham, 2013).  
The UN (UNODC, 2014) have admitted that they are unable to cope with the plethora of new 
substances and, in 2013, the EU put forward proposals to increase their powers to deal with new 
substances more quickly (see Chatwin 2017 in this issue for more details). Birdwell, Chapman & 
Singleton (2011), Coulson & Caulkins (2011) and Hughes & Winstock (2011), all predicted that the 
development of substances and markets that do not fit neatly into existing systems of drug control 
ǁŽƵůĚŶĞĐĞƐƐŝƚĂƚĞƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨŶĞǁĂƉƉƌŽĂĐŚĞƐ ?/ŶƐƵŵ ? “ŶĞǁƉŽůŝĐŝĞƐǁĞƌĞŶĞĞĚĞĚ to meet 
a drug problem that was in a state of flux and arose from a dynamic and rapidly evolving drug 
ŵĂƌŬĞƚ ? ?tŽůĨŐĂŶŐ'Žƚǌ ?ĚŝƌĞĐƚŽƌŽĨƚŚĞD ?ĐŝƚĞĚŝŶdƌĂǀŝƐ ? ? ? ? ? P ? ? ?/ŶƐŽŵĞƵƌŽƉĞĂŶ
countries such as the UK, Poland, Austria, Portugal, and Ireland, new approaches to control of NPS 
ŚĂǀĞďĞĞŶĚĞǀĞůŽƉĞĚďĂƐĞĚƵƉŽŶďƌŽĂĚĚĞĨŝŶŝƚŝŽŶƐŽĨ ‘ƉƐǇĐŚŽĂĐƚŝǀŝƚǇ ? ?ƐŽŵĞƚŝŵĞƐǁŝƚŚŽƵƚ
consideration of harmful outcomes (see Reuter & Pardo, 2017;  Reuter and Pardo, 2016; Stevens et 
al., 2015). 
 
In a similar vein, as increasing attention has been placed on the use of HED, so have new, 
increasingly stringent, policy responses been developed.  For example, in relation to Performance 
and Image Enhancing Drugs (PIED) such as steroids often used by professional athletes, the World 
Anti-Doping Authority (WADA) has consistently promoted the need for a global zero-tolerance 
approach within the sporting world (Mulroony & van de Ven, 2015).  Kimergard (2014) describes 
how this policy framework has been extended to the use of PIEDs by non-professional athletes 
resulting in the targeting of traffickers and, in some cases, the criminalisation of users.   The 
European Commission, for example, released a White Paper on Sport in 2007 which recommended 
4  
  
that the trade in HED should be treated the same as the trade in all illicit drugs. Set against this 
backdrop of a prevailing lack of information about new drugs in general and a period of intensive 
and rapid policy change in response to their emergence we wanted to support and promote, via our 
seminar series in general and this special issue in particular, a critical and social approach to the 
exploration of the impact of new drugs.  
 
Researching NPS 
Although there has been a recent increased emphasis on research involving new drugs, there 
remains a lack of research based evidence in general, and a lack of relevant critical and social 
research in particular, to draw upon when seeking to implement related policies (Measham, 2013; 
K ?ƌŝĞŶ ?ŚĂƚǁŝŶ ?:ĞŶŬŝŶƐ ?DĞĂƐŚĂŵ ? ? ? ? ? ? ?KŶůǇĂƌĞůĂƚŝǀĞůy small number have moved beyond 
ƉƌĞǀĂůĞŶĐĞƚŽĞǆƉůŽƌĞƵƐĞƌĞǆƉĞƌŝĞŶĐĞƐĂŶĚŵŽƚŝǀĂƚŝŽŶƐ ?Ğ ?Ő ?DĐůƌĂƚŚ ?K ?EĞŝůů ? ? ? ? ? ?DĞĂƐŚĂŵ ?
Newcombe, 2016; Measham, Moore, & Østergaard, 2011; Perrone, Helgeson, & Fischer, 2013; van 
Hout & Brennan, 2011; Lauritsen & Rosenberg, 2016; Palamar & Barratt, 2016). Similarly, there are 
only a limited number of policy analyses that critically evaluate the major changes that are taking 
place (Hughes & Winstock, 2011; Kavanagh & Power, 2014; Rychert & Wilkins, 2016; Stevens et al. 
2015; Walsh, 2016; Winstock & Ramsey, 2010).   Finally, research studies tend to consider NPS and 
HED separately without seeking to draw out similarities between the areas of study.  Our special 
issue aims to address these gaps by: (i) drawing attention to the important parallels between the 
study of NPS, HED and traditional illicit drugs; (ii) providing critical analysis of recent new drug 
related policy change; and (iii) exploring the social harms facing vulnerable users of these 
substances. 
  
Parallels in the study of traditional illicit drugs, NPS and HED  
  
Perhaps unsurprisingly, the studies of HED included in this special issue indicate the importance of 
viewing their development as another facet, alongside NPS, of the illegal drugs issue in general.  
Collectively, they demonstrate that HED research can add to our understanding of the cultural and 
societal contexts of drug use in general, as well as the critical analysis of the consequences of drug 
policy implementation.  Both van de Ven & Mulrooney (2017) and Hanley Santos & Coomber (2017) 
emphasise the importance of cultural and societal context to the use or supply of HED and the 
complex patterns of and motivations for use surrounding them.   To expand one example, both 
articles draw heavily on the principles of normalisation (Parker, Aldridge & Measham, 1998) and 
5  
everyday life (South, 1999) which have long been key concepts in the drugs field for those seeking to 
understand recreational drug use.  Van de Ven & Mulrooney (2017) also contribute to debates about 
the social supply of substances in general (Chatwin & Potter, 2014;  Coomber, Moyles & South 2015; 
Potter, 2009) through their work with PIED suppliers, and Hanley Santos & Coomber (2017) provide 
evidence that in an environment where little official information is readily available about 
substances that are newly available on the market, users tend to seek information from their friends 
and fellow users within the bodybuilding community.  This finding mirrors research (see for example 
vĂŶ,ŽƵƚ ?,ĞĂƌŶĞ ? ? ? ? ? ?K ?ƌŝĞŶĞƚĂů ? ? ? ? ? ?ǁŝƚŚEW^ƵƐĞƌƐ ƚŚĂƚ ĚĞŵŽŶƐƚƌĂƚĞƐŽŶĞŽĨƚŚĞƉƌŝŵĂƌǇ
avenues for information about new substances comes from user based discussion forums on the 
internet.  
 
Finally, Dunn, in his critical review of DMAA research evidence, demonstrates that issues around 
policy implementation and associated unintended consequences and/or harms for this HED are 
similar to those posed by the increase in range and availability of NPS and new drugs more widely.  
For example: there is a very limited existing evidence base on which to draw; the potential for harm 
is demonstrated but there is very little understanding of the nature of these harms; and scheduling 
of DMAA in many countries will now impede the ability of future research to provide a stronger 
evidence base.   This special issue therefore offers tentative evidence of the merit of studying NPS 
and HED, not in isolation from each other, but as different faces of the same issue, and furthermore 
asserts that both phenomena should be seen as a part of the overall drugs issue rather than as new 
problems per se.   
 
 
Critical evaluation of policy change inspired by new drugs  
Several of the papers included in this special issue directly take up this issue of policy change: the 
main recommendation here is that it tends to increase and extend policy and legislative responses, 
and is therefore an area worthy of critical examination.  Reuter & Pardo (2017)  W recognising this 
tendency towards law enforcement, regulation and scheduling  W explore (amongst other things) the 
likely effectiveness of legislation that seeks to impose a blanket ban on all psychoactive substances, 
and conclude that it will not provide an effective deterrent either to vulnerable users who are using 
new drugs to stay one ƐƚĞƉĂŚĞĂĚŽĨĚƌƵŐƚĞƐƚŝŶŐƌĞŐŝŵĞƐ ?ŽƌƚŽ ‘ƉƐǇĐŚŽŶĂƵƚƐ ?ǁŚŽĂƌĞĂĐƚŝǀĞůǇ
interested in seeking new psychoactive experiences.  Chatwin (2017) cautions against the tendency 
to encourage uniformity in response to a new facet of the drug problem, such as that presented by 
new drugs.  Instead she recommends allowing and even encouraging a diversity in response, 
6  
  
underpinned by evidence gathering and sharing of instances of best practice, that will allow a variety 
of policy options to emerge.   
 
Two further articles advocate for the merits of further explorations of the role of pleasure in 
understanding the motivations for use of these substances and, importantly, in developing policy 
responses towards them.   There has long been a tendency in drug policy discussions of any type to 
overlook any values, benefits, or possible positive effects from the recreational use of substances in 
general (Measham, 2004; Ritter, 2014).  In an Australian context, Matthews, Sutherland, Peacock, 
van Buskirk, Whittaker, Burns & Bruno (2017) provide a concrete example of the important and 
valuable role that subjective experiences of pleasure can play in determining the likelihood for new 
substances to remain popular, attract users and inspire longevity of use.  Similarly, Alexandrescu 
(2017) explores the seductions of unpredictable encounters of drug use that are provided by new 
drugs, particularly among groups of Romanian experienced and long-term users who have become 
problematic in some aspects of their use.  Both papers aim to provide important lessons for the 
development of policy towards NPS. 
  
  
New drug use within vulnerable populations  
 
Many of the articles in our special issue attest to the persistent and problematic use of new drugs 
amongst vulnerable populations: for example, ƐĞĞůĂĐŬŵĂŶ ?ƌĂĚůĞǇ ?Ɛ ? ? ? ? ? ?h<ďĂƐĞĚƌĞƐĞĂƌĐŚ
ŽŶǀƵůŶĞƌĂďůĞǇŽƵŶŐƉĞŽƉůĞĂŶĚƐǇŶƚŚĞƚŝĐĐĂŶŶĂďŝŶŽŝĚƵƐĞ ?ZĂůƉŚƐ ?tŝůůŝĂŵƐ ?ƐŬĞǁ ?zŬŚůĞĨ ?Ɛ
 ? ? ? ? ? ?ƌŝƚŝƐŚƐƚƵĚǇŽĨƐǇŶƚŚĞƚŝĐĐĂŶŶĂďŝŶŽŝĚŵĂƌŬĞƚƐŝŶĂůŽĐĂůƉƌŝƐŽŶ ?ůĞǆĂŶĚƌĞƐĐƵ ?Ɛ ? ? ? ? ? ?
exploration of NPS use among existing methadone users in Romania; and Quintana, Ventura, Grifell, 
WĂůŵŽ ?'ĂůŶĚŽ ?&ŽƌŶŝƐ ?'ŝů ?ĂƌďŽŶ ?ĂƵĚĞǀŝůůĂ ?&ĂƌƌĞ ?dŽ ƌĞŶƐ ?Ɛ ? ? ? ? ? ?^ƉĂŶŝƐŚďĂƐĞĚƌĞƐĞĂƌĐŚŽŶ
the adulteration of heroin products available online.   Existing research on new drug use within 
vulnerable populations tends to be very limited  W HMIP (2015) and User Voice (2016) have both 
sought to emphasise the elevated use of new drugs within the English prison system and the 
particular harms that this can cause, and Public HĞĂůƚŚŶŐůĂŶĚ ?Ɛ ? ? ? ? ? ?ƌĞĐĞŶƚƐƵƌǀĞǇŽĨƚŚĞ
treatment population found that 8.2% of respondents reported injecting mephedrone in the past 
year, and these were twice as likely to report sharing injecting equipment than other people who 
injected drugs.  The contributions included in our special issue concerning vulnerable populations 
and new drug use provide valuable new insights into this area and, furthermore, strongly suggest the 
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need for our research efforts to be concentrated here, rather than in the more popular area of 
recreational and experimental use of new drugs.  
 
Two articles directly address the issue of service provision for problematic new drug users.  
ĂŵƉďĞůů ?K ?EĞŝůů ?,ŝŐŐĞŶƐ ? ? ? ? ? ?ŚĂǀĞĐŽŶĚƵĐƚĞĚĂƌĞƐĞĂƌĐŚƐƚƵĚǇŽĨƐĞƌǀŝĐĞƉƌŽǀŝĚĞƌƐŝŶEŽƌthern 
Ireland who are frequently in contact with new drug users, and Pirona, Bo, Hedrich, Ferri, van 
Gelder, Giraudon, Montanari, Simon & Mountenay (2017) have presented a comprehensive 
exploration of current health responses to new drugs in operation in Europe, seeking to highlight key 
issues and instances of best practice.  Both articles highlight the continuing gaps in service provision 
for vulnerable groups such as young people, polydrug users and mental health populations, and the 
need for new drugs to be considered at every stage of drug prevention and education interventions. 
This issue is particularly complex as, paradoxically, evidence suggests that on the one hand many 
users of new drugs are also users of traditional drugs indicating that their drug use should be treated 
holistically, while on the other hand users have called for service provision that focuses on the 
specific needs of the users of new substances.  Campbell et al (2017), thus emphasise the need for 
increased knowledge not only about new drugs, but also about the intersections between traditional 
drugs, NPS and HED.   
 
In terms of harm reduction our articles collectively suggest, we should promote the more 
widespread introduction of drug checking and testing  facilities, build information about a variety of 
new drugs into our existing drug and alcohol education programmes, and encourage the distribution 
of harm reduction information via existing peer networks of users.  Sometimes, the emergence of 
NPS and the challenges of intertwining traditional and new drug markets, has prompted the 
introduction of harm reduction measures  W see, for example, the initiation of on-site forensic testing 
for safety for the first time in countries such as the UK and Australia (Measham, 2016).  The article 
by van Hout & Hearne on forum activity between buyers and vendors in cryptomarkets provides 
some further evidence of this trend by documenting the centrality of harm reduction practices and 
vendor information exchange to NPS market dynamics in general.  
  
  
Conclusion: towards a critical and social research agenda for new drugs  
  
One factor that is usually agreed upon by a variety of experts working in related fields, is that we 
urgently need more information about new drugs in general  W both new psychoactive substances 
8  
  
and human enhancement drugs.  Without a better evidence base for policy makers and practitioners 
to draw upon, it is very difficult to make any meaningful progress in responding to the new drug 
phenomenon.  Despite the prioritisation of the new drugs issue, sometimes over and above more 
ƉƌĞǀĂůĞŶƚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ĚƌƵŐƐ ?ĂƚůĞĂƐƚŝŶƚĞƌŵƐŽĨEW^ ?ĂĐŽŚĞƌĞŶƚĂŶĚĞǆƚĞŶƐŝǀĞƐŽĐŝĂůƌĞƐĞĂƌĐŚ
agenda in this area that seeks to evaluate policies and their consequences, critically assess official 
discourses, evaluate supply and demand, particularly within online markets, and explore the needs 
and experiences of users does not yet exist.  Based on the articles included in this special issue, as 
well as our wider work within the ESRC seminar series as a whole, we offer the following brief 
outline of future research needs and challenges.  
 
Firstly, new drugs research should pay more attention to the intersections between traditional drugs, 
NPS and HED.  There are important similarities that merit the study of different substances, or 
categories of substance, side by side; but there are also important differences that, for example, can 
lead to different treatment needs.  Future research should seek to tease out these similarities and 
differences.  Secondly, we need to assess and evaluate the new legislative landscapes that are 
developing as a direct result of rising anxieties about new drugs, often based around precautionary 
principles rather than strong evidence of harm and the need for intervention.  Finally, and perhaps 
most importantly, we need to concentrate our combined research efforts on the exploration of new 
drug use amongst vulnerable populations such as the prison population and those who have recently 
been released from prison, the homeless, and those who are experiencing mental health problems. 
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